Core Viewpoint - Heng Rui Medicine (600276)(01276) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Summary by Category Company Actions - The company plans to repurchase 235,000 A-shares at a total cost of 15.9266 million RMB [1] - The buyback price per share ranges from 67.2 to 68.41 RMB [1] Financial Implications - The total expenditure for the buyback represents a strategic investment in the company's own shares, potentially enhancing shareholder value [1]

格隆汇9月11日丨恒瑞医药(01276.HK)发布公告，2025年9月11日耗资人民币1592.7万元回购23.5万股A 股，回购价格每股67.2-68.41元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江蘇恒瑞醫藥股份有限公司 呈交日期： 2025年9月11日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 600276 | 說明 | A股（於上海證券交易所上市） | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括 ...

A股主要指数今日集体大涨，深成指、创业板指续创阶段新高；截至收盘，沪指涨1.65%报3875点，深证成 指涨3.36%创2022年7月以来新高，创业板指涨5.15%创2022年1月以来新高，科创50指数涨5.32%。全天成交 额2.46万亿元，较前一交易日增量4606亿元，全市场超4200股上涨。 盘面上，CRO板块下挫，诺思格、泰格医药领跌，港股通创新药ETF嘉实、恒生创新药ETF、 港股创新药 ETF基金、港股创新药ETF、港股创新药50ETF、恒生医药ETF、恒生生物科技ETF跌超2%。 | 证券代码 | 证券简称 | 当日涨跌幅% | | --- | --- | --- | | 520970.SH | 港股通创新药ETF嘉实 | -2.32% | | 159316.SZ | 恒生创新药ETF | -2.30% | | 520700.SH | 港股创新药ETF基金 | -2.29% | | 513120.SH | 港股创新药ETF | -2.25% | | 513780.SH | 港股创新药50ETF | -2.06% | | 159892.SZ | 恒生医药ETF | -2.06% | | 15961 ...

↑点击上面图片 加雪球核心交流群 ↑ 今天行情再度燃爆，休整几天后，牛市的气息又回来了！ 市场全天持续走强 ， 三大指数强势反弹 ， 创业板指和 深成指 双双再创年内新高，截至收盘，沪指 涨1.65% ， 深成指涨3.36% ， 创业板指涨 5.15%。 沪深两市成交额2.44万亿 ， 较上一个交易日放量4596亿， 全市场超4200只个股上涨 。 工业富联2连板 算力硬件股再度成为市场焦点，液冷、CPO、PCB等多个方向上涨，截至收盘，胜宏科技涨超16%，中际旭创涨超14%、新易盛涨超13%、天孚 通信涨超13%、寒武纪涨近9%，景旺电子、东山精密、剑桥科技等多股涨停。 | 性宏科技 | | | | | --- | --- | --- | --- | | 300476 盘后交易09-11 15:15:30 北京 | | | | | 338.00 +47.33 +16.28% | | 13.25万人加自选 二 > CN 融 通 L1 | | | 高 345.88 开 300.26 | 量 92.94万手 | 总市值 2915.89亿 | | | 低 290.43 换 10.87% | 额 291.43亿 | ...

转自：新华财经 新华财经北京9月11日电 （胡晨曦）新华500指数（989001）9月11日收盘涨2.44%，报5020.17点。 走势上看，新华500指数（989001）11日早间微有低开，随后上行翻红，指数全天震荡上扬，最终显著收涨。指数盘中最高触及5020.17点，最低触及4894.73 点，成分股全天总成交额报9448亿元，成交额较上一交易日明显增加。 成分股方面，中际旭创、工业富联、生益科技 、深南电路等成分股涨幅居前；泰格医药、朗新集团、华海药业、恒瑞医药等成分股跌幅靠前。 新华500指数由国家金融信息平台•新华财经发布，新华指数（北京）有限公司运营维护，指数度量A股主要大中市值股票价格水平。关于新华500指数的详 细信息，请参见新华财经客户端。 编辑：王媛媛 ...

Market Overview - The A-share market experienced a significant rally, with the Shanghai Composite Index rising by 1.65%, the Shenzhen Component increasing by 3.36%, the ChiNext Index up by 5.15%, and the North China 50 gaining 1.59% [1] - The total trading volume across Shanghai, Shenzhen, and Beijing reached 24,646 billion yuan, an increase of 4,606 billion yuan compared to the previous day [1] - Over 4,200 stocks in the market saw an increase [1] Sector Performance - Technology stocks, particularly in CPO, copper cable high-speed connections, semiconductors, photolithography machines, and satellite communications, led the gains [1] - Conversely, sectors such as precious metals, oil and gas, film and television, tourism, dairy, and CRO concept stocks lagged behind [1] Notable Stocks - The computing hardware sector, including CPO and semiconductors, saw widespread gains, with Haiguang Information hitting a 20% limit up and achieving a new high [1] - Industrial Fulian experienced consecutive limit-up days, while stocks like Zhongji Xuchuang, Shenghong Technology, Xinyisheng, and Tianfu Communication surged over 10% [1] - More than 20 stocks in the computing hardware sector reached their daily limit [1] - Pork stocks showed high volatility, with Jin Xin Nong, Bang Ji Technology, and Tian Kang Biological hitting the limit up [1] - The securities sector rebounded, with Guohai Securities reaching the limit up [1] - On the other hand, the precious metals sector saw most stocks adjust, including Western Gold and Sichuan Gold [1] - Innovative drug concept stocks experienced a sharp decline in the morning, with stocks like Tigermed, Zhaoyan New Drug, and Hengrui Medicine falling [1]

Core Viewpoint - China's new drug research and development capabilities have risen to the second position globally, with multiple domestic innovative drugs receiving approval for market entry, filling gaps in relevant fields [4][5]. Industry Developments - The National Health Commission announced that the number of new drugs under research in China accounts for over 20% of the global total, marking a significant achievement in the country's pharmaceutical sector [4]. - Several innovative drugs, including Sugliatin, Ensartinib, and Gilteritinib, have been approved and are now available in the market, addressing unmet medical needs [4]. - The self-developed anti-tumor drug, Zebutinib, has also received approval in multiple countries, indicating a successful international expansion [5]. Market Performance - The A-share and Hong Kong stock markets saw a collective downturn in the innovative drug sector, with significant declines in leading stocks [6][7]. - The Hong Kong CRO index dropped by 4.11%, with notable stocks like Gilead Sciences experiencing a decline of over 16% [8]. - By midday, several stocks, including Tigermed and BeiGene, reported declines of over 10% and 6%, respectively, reflecting a broader market weakness [9][11]. Investment Outlook - Despite the current market adjustments, institutions maintain a medium to long-term optimistic outlook for the innovative drug sector [12]. - Reports from Guotai Junan Securities suggest that the quality of financial reports in the innovative drug sector will improve by 2025, with more products entering the national medical insurance system [12]. - Analysts recommend focusing on sectors with strong domestic demand and performance certainty, particularly in innovative-driven and internationalization strategies [12].

【导读】我国跃居全球新药研发第二位，多款国产创新药获批上市 中国基金报记者张舟 9月11日上午，创新药领域迎来"冰火两重天"。 一方面，国新办新闻发布会释放行业重磅利好，宣布我国新药研发实力跻身全球第二，多款国产创新药落地填补相关领域空白；另一方 面，A股及港股创新药相关板块出现调整，龙头个股集体下挫。 机构认为，创新药行情开始分化，当前需要精选个股，中长期保持乐观态度。 国家卫健委：多款国产创新药陆续获批上市 填补相应领域空白 今日上午，国新办举行"高质量完成'十四五'规划"系列主题新闻发布会，国家卫生健康委副主任、国家疾控局局长沈洪兵，国家卫生健 康委副主任郭燕红，国家卫生健康委党组成员、国家中医药局局长余艳红介绍"十四五"时期卫生健康工作发展成就，并答记者问。 同日，香港财政司司长陈茂波在出席某生物科技投资峰会时指出，生物科技领域有无限机遇，中国目前是全球第二大生物制药市场，正 崛起成为生物科技领导者。他强调，香港可以作为进入内地市场的门户，也是内地创新成果走向世界的平台。 A股、港股创新药板块集体承压 二级市场方面，今早，A股、港股市场创新药板块集体承压。 港股市场上，港股CRO指数大跌4.11%，歌 ...

当地时间9月6日-9月9日，在西班牙巴塞罗那举办的2025年世界肺癌大会上，超百款创新药亮相，多家 本土创新药龙头企业在会议期间发布重磅新品研究成果，与跨国企业的创新药同台亮相，中国创新药在 国际上的认可度不断提升。作为全球肺癌研究领域最具影响力的学术盛会之一，国际肺癌研究协会举办 的世界肺癌大会汇聚了来自世界各地的顶尖肿瘤专家、科研人员，共同探讨肺癌领域的最新研究进展和 治疗突破。 全球重磅肺癌新药研究进展受关注 肺癌是癌症死亡的主要原因之一，约占所有癌症死亡患者数的五分之一 ，其中非小细胞肺癌约占所有 肺癌患者的80%-85% 。美国和欧洲的非小细胞肺癌患者中约有10%-25%存在EGFR突变，而亚洲患者中 该比例则高达30%-40%。针对这一"头号杀手"，多年来，全球科学家一直在努力开展针对肺癌的各种创 新药物研究。近年来，靶向药和免疫药物的研发和上市进程加快，让肺癌治疗步入黄金时代。 据迪哲医药9月10日公告，本次大会上，迪哲医药报告了其自主研发的新型肺癌靶向药舒沃替尼片（商 品名：舒沃哲）和高选择性JAK1抑制剂戈利昔替尼胶囊（商品名：高瑞哲）在非小细胞肺癌领域的11 项最新研究。其中，舒沃哲国际多 ...